No Data
Year Wrapped: Tryptamine Therapeutics 2024 Milestones, Clinical Breakthroughs & 2025 Vision | ASX:TYP, OTC:TYPTF
Tryptamine Therapeutics Fields Positive Early Results in Phase 2a Irritable Bowel Syndrome Trial
Tryptamine Therapeutics Phase 1b Study Refines Dose of IV Psilocin in Obese Subjects
Tryptamine Therapeutics Issues 47 Million Unquoted Options
Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study
Tryptamine Therapeutics Doses First Patient in IV-infused Psilocin Phase 1b Study
No Data